Kiniksa Pharmaceuticals Provides Corporate Update

– ARCALYST (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) –

– ARCALYST 2024 net product revenue expected to be $360 - $380 million –

– Abiprubart (KPL-404) Phase 2 rheumatoid arthritis trial met the primary efficacy endpoint in Cohort 3 at the weekly dose level –

– Abiprubart Phase 2 rheumatoid arthritis data from Cohort 4 expected in Q2 2024 –

– Cash reserves of $206.3 million (unaudited) expected to fund operations into at least 2027–

HAMILTON, Bermuda, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today provided a corporate update.

"Strong execution to date has laid the foundation for the continued advancement of Kiniksa’s portfolio in 2024. ARCALYST 2023 net product revenue grew ~90% year-over-year to $233.1 million, underscoring our robust commercial performance. We believe there is substantial opportunity with ARCALYST in recurrent pericarditis and expect to drive continued revenue growth and collaboration profitability by reaching an increasing number of patients. In fact, at the end of 2023 Kiniksa penetrated approximately 9% into the multiple-recurrence population, compared to approximately 5% at the end of 2022,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “Additionally, abiprubart showed clinical effect in the first three cohorts of the Phase 2 trial in rheumatoid arthritis. Despite a high placebo response rate, the 5 mg/kg weekly dose level in Cohort 3 achieved statistical significance, but the 5 mg/kg biweekly dose level did not. We look forward to evaluating results from Cohort 4, and we will use the totality of the data to determine next steps for the program. Importantly, our strong financial position provides optionality to continue to invest across our business, including ARCALYST commercialization as well as both pipeline and business development.”

Portfolio Execution
ARCALYST (IL-1α and IL-1β cytokine trap)

• ARCALYST net product revenue was $71.2 million and $233.1 million for the fourth quarter and full year 2023, respectively (unaudited).
• Since launch in April 2021, more than 1,700 prescribers have written ARCALYST prescriptions for recurrent pericarditis.
• As of the end of the fourth quarter of 2023, average total duration of ARCALYST therapy in recurrent pericarditis increased to approximately 23 months.
• As of the end of the fourth quarter of 2023, approximately 9% of the target 14,000 multiple-recurrence patients were actively on ARCALYST treatment.
• Kiniksa increased the size of its salesforce to approximately 85 representatives by the end of 2023 to help drive further physician adoption and patient enrollments in 2024.
• Kiniksa expects 2024 ARCALYST net product revenue of between $360 million and $380 million.

Abiprubart (anti-CD40 monoclonal antibody inhibitor of CD40-CD154 interaction)